qPCR analysis also confirmed that Mit-A inhibition of the CT26 tumor growth correlated to the reduced expression of CD133 (Fig. 7E) suggesting that Mit-A targets CSCs in vivo. This evidence concerns the gene PROM1 and neoplasm.